Close window

FDA panel backs drug for early stage breast cancer
This undated photo provided by Roche, shows the initial treatment drug Perjeta The U.S. Food and Drug Administration has issued a positive review of Perjeta, a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery. (AP Photo/Roche)

Close this window   |   See more photo galleries   |   Return to